|
|
Article: Connetics Completes Soriatane Acquisition.
- Article from:
- PR Newswire
- Article date:
- March 4, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Connetics Corporation , a specialty pharmaceutical company focused on dermatology, today announced that it has acquired exclusive U.S. rights to Roche's Soriatane(R)-brand (acitretin), an approved oral therapy for the treatment of severe psoriasis in adults. On February 6, 2004, Connetics announced its intent to purchase Soriatane from Roche for $123 million in cash. Soriatane is a once-daily oral medication, available in 10 mg and 25 mg capsules, for initial and maintenance treatment of severe psoriasis in adults.
"Soriatane is a proven therapy, which has been studied in five types of psoriasis, and has an extensive record of clinical use in more than one ...